CGH

Cielo Global Holdings Announces CieloPay Executive Leadership

Retrieved on: 
Tuesday, June 4, 2019
CGH

LUBBOCK, Texas, June 4, 2019 /PRNewswire/ --Cielo Global Holdings (CGH) has named Nabil Kabbani President and CEO of CieloPay, a CGH portfolio company.

Key Points: 
  • LUBBOCK, Texas, June 4, 2019 /PRNewswire/ --Cielo Global Holdings (CGH) has named Nabil Kabbani President and CEO of CieloPay, a CGH portfolio company.
  • Kabbani was the CEO of CommerceGate, a payment processing company in the e-commerce arena prior to joining ACT Holdings.
  • "The addition of Nabil's expertise to our CGH team is extremely advantageous for the CieloPay brand," said BJ Carter, CEO, Cielo Global Holdings.
  • www.cielopay.com
    Cielo Global Holdings (CGH) specializes in managing and investing in disruptive technology companies delivering solutions through our CGH portfolio companies - CieloIT, CieloPay, CieloGov, and CieloAlliance.

Biochip/Microarray Markets, 2028

Retrieved on: 
Tuesday, May 21, 2019
Branches of biology, Biology, Genetics, Molecular biology, Microarrays, DNA, Biotechnology, Genomics, Comparative genomic hybridization, Biochip, DNA methylation, CGH

DUBLIN, May 21, 2019 /PRNewswire/ -- The "Biochips - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 21, 2019 /PRNewswire/ -- The "Biochips - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • The report starts with a description of technologies as a basis for estimation of markets.
  • Technologies include array comparative genomic hybridization (CGH), copy number variation (CNV), DNA methylation, ChIP-Chip, RNA splice variants, and microRNA.
  • Separate chapters are devoted to applications in drug discovery and development as well as personalized medicine
    The report provides current share of each segment: market size in 2018 and projected value for the years 2023 and 2028.

Global Biochips Markets Report, 2019: Analysis & Forecasts of Biochip/Microarray Markets 2018-2023 & 2028 Featuring Profiles of 92 Companies & Their 121 Collaborations

Retrieved on: 
Tuesday, March 19, 2019
Branches of biology, Genetics, Biology, Molecular biology, DNA, Microarrays, Biotechnology, Genomics, Comparative genomic hybridization, Biochip, DNA methylation, CGH

DUBLIN, March 19, 2019 /PRNewswire/ -- The "Biochips - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 19, 2019 /PRNewswire/ -- The "Biochips - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • The report starts with a description of technologies as a basis for estimation of markets.
  • Technologies include array comparative genomic hybridization (CGH), copy number variation (CNV), DNA methylation, ChIP-Chip, RNA splice variants, and microRNA.
  • Currently selected 92 companies are included along with listing of 121 collaborations between companies.

Global Cytogenetics Technologies, Companies and Markets to 2027

Retrieved on: 
Wednesday, August 22, 2018
Biology, Cytogenetics, Laboratory techniques, Molecular biology, Genetics, Comparative genomic hybridization, Fluorescence in situ hybridization, Nucleic acid hybridization, CGH, In situ hybridization, Molecular Cytogenetics, Metaphase

The "Cytogenetics - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cytogenetics - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • Historical landmarks in the evolution of cytogenetics are reviewed since the first images of chromosomes were made in 1879.
  • The scope of cytogenetics includes several technologies besides fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and multicolor FISH.
  • The chapter on markets provides a global perspective of the cytogenetics business in the major markets: US, Western Europe (including France, Germany, Italy, Spain, and the UK), and Japan.